Ropes & Gray has represented Verastem Oncology in a public offering of common stock and pre-funded warrants valued at $90 million. The pricing of the offering was announced on November 14 and closed November 17.
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers.
The deal team was led by capital markets partner Tom Danielski and included tax partner Pamela Glazier.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.